Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.
Frequently asked questions
What sector does Gemina Laboratories Ltd (GLABF) operate in?
Gemina Laboratories Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Gemina Laboratories Ltd (GLABF) current stock price?
As of the latest data, Gemina Laboratories Ltd stock price is $0.05, with a previous close of $0.05.
What is Gemina Laboratories Ltd (GLABF) current market capitalization?
Gemina Laboratories Ltd market cap is approximately 3.83 million.
What is Gemina Laboratories Ltd (GLABF) Earnings Per Share (EPS)?
The trailing EPS is -$0.03.
Does Gemina Laboratories Ltd (GLABF) pay dividends?
No. Gemina Laboratories Ltd does not pay a dividend.
What is Gemina Laboratories Ltd (GLABF) beta (volatility) score?
Gemina Laboratories Ltd has a beta of 0.010, indicating lower volatility than the overall market.